Etiotropic therapy of the new coronavirus infection. Expectations and realities. Part 2
- 作者: Kuznetsova O.Y.1
-
隶属关系:
- North-Western State Medical University named after I.I. Mechnikov
- 期: 卷 26, 编号 2 (2022)
- 页面: 7-12
- 栏目: Review
- URL: https://journals.rcsi.science/RFD/article/view/108485
- DOI: https://doi.org/10.17816/RFD108485
- ID: 108485
如何引用文章
详细
Part 2 of the review includes an analysis of the literature data related to the etiotropic therapy of a new coronavirus infection using drugs from the group of monoclonal antibodies and viral protease inhibitors. The difficulty of choosing a drug for the treatment of a new coronavirus infection caused by the Omicron strain due to the high degree of mutation is emphasized. The mechanism of action of the combined drug Paxlovid, consisting of nirmatrelvir and ritonavir, is described, data on its high efficacy and safety obtained in randomized multicenter placebo-controlled trials are presented. Attention is drawn to the World Health Organization recommendations on the use of this drug in people at high risk of a severe course of a new coronavirus infection and the need for early diagnosis of clinical symptoms for the timely appointment of etiotropic therapy.
作者简介
Olga Kuznetsova
North-Western State Medical University named after I.I. Mechnikov
编辑信件的主要联系方式.
Email: oukuznetsova@mail.ru
ORCID iD: 0000-0002-2440-6959
SPIN 代码: 7200-8861
Scopus 作者 ID: 24448739500
Researcher ID: O-4056-2014
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Saint Petersburg参考
- Otslezhivanie variantov virusa SARS-CoV-2 [Internet]. WHO. Available from: https://www.who.int/ru/activities/tracking-SARS-CoV-2-variants. Accessed: June 2, 2022. (In Russ.)
- Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. doi: 10.1016/j.cell.2021.12.032
- Vremennye metodicheskie rekomendatsii. Diagnostika, profilaktika i lechenie novoi koronavirusnoi infektsii (COVID-19), versiya 14 (27.12.2021) [Internet]. Available from: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/1213/attach/vmr_COVID-19_V14_27-12-2021.pdf. Accessed: June 2, 2022
- Lekarstvennaya terapiya pri COVID-19. Variativnye rekomendatsii. 24.09.2021 [Internet]. Available from: https://apps.who.int/iris/bitstream/handle/10665/345356/WHO-2019-nCoV-therapeutics-2021.3-rus.pdf. Accessed: June 2, 2022. (In Russ.)
- Postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 03.04.2020 No. 441 [Internet]. Ofitsial’nyi internet-portal pravovoi informatsii (pravo.gov.ru). Available from: http://publication.pravo.gov.ru/Document/View/0001202004060038. Accessed: June 2, 2022. (In Russ.)
- Heo YA. Sotrovimab: First Approval. Drugs. 2022;82(4):477–484. doi: 10.1007/s40265-022-01690-7
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial. medRxiv. 2021. doi: 10.1101/2021.11.03.21265533
- Spravochnik lekarstvennykh sredstv VIDAL [Internet]. Available from: https://www.vidal.ru/novosti/preparat-sotrovimab-dlya-lecheniya-covid-19-legkoj-i-srednej-stepeni-tyazhesti-u-patsientov-10462. Accessed: June 2, 2022. (In Russ.)
- Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
- COVID-19 Treatment Guidelines [Internet]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/?utm_source=site&utm_medium=home&utm_campaign=highlights. Accessed: June 2, 2022.
- Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. doi: 10.1136/bmj.n2713
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
- VOZ rekomenduet k primeneniyu effektivnoe lekarstvo ot COVID-19 [Internet]. WHO. Available from: https://news.un.org/ru/story/2022/04/1422402. Accessed: June 2, 2022. (In Russ.)
- Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022. Vol. 386, No. 4. 305–315. doi: 10.1056/NEJMoa2116846
- WHO recommends against the use of remdesivir in COVID-19 patients [Internet]. Available from: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients. Accessed: June 2, 2022.
补充文件
